Valuation: Wockhardt Limited

Market Cap 372B 3.87B 3.41B 3.21B 2.93B 5.48B 5.52B 38.53B 14.93B 189B 14.54B 14.22B 616B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 387B 4.03B 3.55B 3.35B 3.05B 5.71B 5.75B 40.14B 15.56B 197B 15.15B 14.82B 641B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.98%
Yield 2025 *
-
Yield 2026 -
1 day-0.97%
1 week+8.60%
Current month+20.27%
1 month+19.27%
3 months+15.29%
6 months+89.24%
Current year+56.66%
1 week 2,090
Extreme 2090
2,360
1 month 1,833.3
Extreme 1833.3
2,360
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 213.25
Extreme 213.25
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 01/04/2009
Director of Finance/CFO - 01/03/2022
Chief Tech/Sci/R&D Officer - 01/05/1998
Director TitleAgeSince
Chairman 83 06/11/2009
Director/Board Member 53 06/11/2009
Director/Board Member 55 01/07/1996
Change 5-day change 1-year change 3-year change Capi.($)
-0.97%+8.60%+53.49%+882.05% 3.87B
+0.12%+0.81%+13.81%+64.78% 46.24B
+1.09%+0.36%+39.50%+107.67% 36.48B
+2.00%+3.78%+18.12%+99.54% 12.27B
+0.05%+0.37%-7.29%+18.68% 11.77B
0.00%-0.95%+18.72%+140.74% 8.95B
-2.07%-2.75%+17.20%+202.97% 7.14B
-0.55%-1.95%+28.70%+38.62% 7.16B
+1.43%+2.22%+43.10%-14.21% 7.12B
-2.45%+0.10%-49.83%+8.04% 4.99B
Average -0.14%+1.30%+17.55%+154.89% 14.6B
Weighted average by Cap. +0.31%+0.01%+20.40%+100.73%

Financials

2025 2026
Net sales 30.35B 316M 278M 262M 239M 447M 451M 3.15B 1.22B 15.45B 1.19B 1.16B 50.26B 34.62B 361M 317M 299M 273M 510M 514M 3.59B 1.39B 17.62B 1.35B 1.32B 57.34B
Net income -470M -4.9M -4.31M -4.06M -3.7M -6.93M -6.98M -48.72M -18.88M -239M -18.38M -17.98M -778M 2.13B 22.19M 19.52M 18.4M 16.79M 31.39M 31.64M 221M 85.56M 1.08B 83.31M 81.5M 3.53B
Net Debt 14.33B 149M 131M 124M 113M 211M 213M 1.49B 576M 7.29B 560M 548M 23.73B 15.53B 162M 142M 134M 122M 229M 231M 1.61B 624M 7.9B 607M 594M 25.72B
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
25/09/26 ₹2,265.60 -0.97% 689,934
24/09/26 ₹2,287.70 -1.80% 824,745
23/09/26 ₹2,329.70 +6.60% 3,834,525
22/09/26 ₹2,185.40 -0.09% 1,006,397
21/09/26 ₹2,187.30 +4.85% 1,771,282
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock